Form 4: Edgewise Therapeutics CEO Kevin Koch Reports Stock Option and Restricted Stock Unit Grants

Kevin Koch, CEO of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On August 12, 2024, Kevin Koch, the President and CEO of Edgewise Therapeutics, was granted stock options to purchase 431,250 shares of common stock at an exercise price of $17.05 per share.
• These options vest monthly over a four-year period, starting August 12, 2024.
• Koch also received 71,875 restricted stock units (RSUs), each representing a contingent right to receive one share of Edgewise Therapeutics common stock.
• These RSUs vest in four equal annual installments beginning on August 12, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management with shareholder interests.

Positives

• The grant of stock options and RSUs to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and amounts granted are generally benchmarked against peer companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize the CEO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates